Skip to content
value.today

Regulus Therapeutics Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2009
Total raised
$141 M
8 rounds on record
Latest round
$35 M
Nov 2021
First round on record
Mar 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Regulus Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$35 MNo. 8$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 8, Nov 2021

Investors in this round

16 investors had bought by the notice of Dec 6, 2021: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,077,499
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Aker · Executive Officer
  • Cris Calsada · Executive Officer
  • Denis Drygin · Executive Officer
  • Joseph Hagan · Executive Officer, Director
  • Alice S. Huang · Director
  • David Baltimore · Director
  • Hugh H. Rosen · Director
  • Jake R. Nunn · Director
  • Kathryn J. Collier · Director
  • Pascale H. Witz · Director
  • Simos H. Simeonidis · Director
  • Stelios Papadopoulos · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H. C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, IL, MD, NY, PA, TX
  • SVB Leerink LLC (CRD 39011) · Boston, MassachusettsSold in CA, IL, MD, NY, PA, TX

Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed Dec 6, 2021. Read the notice at the SEC.

equitySEC
Dec 2020$19 MNo. 7$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 7, Dec 2020

Investors in this round

18 investors had bought by the notice of Dec 17, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$19 M of $35 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,066,067
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Aker · Executive Officer
  • Cris Calsada · Executive Officer
  • Denis Drygin · Executive Officer
  • Joseph Hagan · Executive Officer, Director
  • David Baltimore · Director
  • Hugh H. Rosen · Director
  • Jake R. Nunn · Director
  • Kathryn J. Collier · Director
  • Pascale H. Witz · Director
  • Simos H. Simeonidis · Director
  • Stelios Papadopoulos · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H. C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, CO, CT, MD, NY, OH, TX

Remarks in the notice

  • On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”

Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed Dec 17, 2020. Read the notice at the SEC.

equity, optionsSEC
May 2019$17 MNo. 6$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 6, May 2019

Investors in this round

21 investors had bought by the notice of May 14, 2019: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $79 M offered; $63 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,301,322
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher R. Aker · Executive Officer
  • Daniel R. Chevallard · Executive Officer
  • Joseph P. Hagan · Executive Officer, Director
  • David R. Baltimore · Director
  • Hugh H. Rosen · Director
  • Kathryn L. Collier · Director
  • Pascale H. Witz · Director
  • Stelios R. Papadopoulos · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright Co. (CRD 375) · New York, New YorkSold in CA, CT, MA, MD, NY

Remarks in the notice

  • On fees: “"""Sales Commissions"" includes amounts payable by the Issuer for both the initial closing and the milestone closing."”
  • On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”

Signed by Christopher Aker, Sr. VP and General Counsel. Source: SEC Form D, newest notice filed May 14, 2019. Read the notice at the SEC.

equity, optionsSEC
Feb 2014$10 MNo. 5$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 5, Feb 2014

Investors in this round

1 investor had bought by the notice of Feb 6, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kleanthis Xanthopoulos · Executive Officer, Director
  • Neil Lynne Gibson · Executive Officer
  • B. Lynne Parshall · Director
  • Bruce L.A. Carter · Director
  • David Baltimore · Director
  • Douglas E. Williams · Director
  • John H. Maraganore · Director
  • Mark G. Foletta · Director
  • Stelios H. Papadopoulos · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Feb 6, 2014. Read the notice at the SEC.

equitySEC
Oct 2012$25 MNo. 4$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 4, Oct 2012

Investors in this round

1 investor had bought by the notice of Oct 23, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Lynne Menzel · Executive Officer
  • Kleanthis Xanthopoulos · Executive Officer, Director
  • Neil Lynne Gibson · Executive Officer
  • B. Lynne Parshall · Director
  • Barry E. Greene · Director
  • Bruce L.A. Carter · Director
  • David Baltimore · Director
  • John E. Maraganore · Director
  • Stanley Crooke · Director
  • Stelios E. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Oct 23, 2012. Read the notice at the SEC.

equitySEC
Aug 2012$5 MNo. 3$2 to $10 million

Regulus Therapeutics Inc.: Raise no. 3, Aug 2012

Investors in this round

1 investor had bought by the notice of Oct 23, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Lynne Menzel · Executive Officer
  • Kleanthis Xanthopoulos · Executive Officer, Director
  • Neil Lynne Gibson · Executive Officer
  • B. Lynne Parshall · Director
  • Barry E. Greene · Director
  • Bruce L.A. Carter · Director
  • David Baltimore · Director
  • John E. Maraganore · Director
  • Stanley Crooke · Director
  • Stelios E. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher Aker, Corp. Secretary. Source: SEC Form D, newest notice filed Oct 23, 2012. Read the notice at the SEC.

debt, optionsSEC
Oct 2010$10 MNo. 2$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 2, Oct 2010

Investors in this round

1 investor had bought by the notice of Nov 15, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Lynne Menzel · Executive Officer
  • Grantland Lynne Bryce · Executive Officer
  • Kleanthis Xanthopoulos · Executive Officer, Director
  • B. Lynne Parshall · Director
  • Barry E. Greene · Director
  • David Baltimore · Director
  • John E. Maraganore · Director
  • Stanley Crooke · Director
  • Stelios E. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC.

equitySEC
Mar 2009$20 MNo. 1$10 to $50 million

Regulus Therapeutics Inc.: Raise no. 1, Mar 2009

Investors in this round

2 investors had bought by the notice of Nov 15, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Lynne Menzel · Executive Officer
  • Grantland Lynne Bryce · Executive Officer
  • Kleanthis Xanthopoulos · Executive Officer, Director
  • B. Lynne Parshall · Director
  • Barry E. Greene · Director
  • David Baltimore · Director
  • John E. Maraganore · Director
  • Stanley Crooke · Director
  • Stelios E. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC.

equitySEC
Jan 2009$30 MIssued in a merger or acquisition$10 to $50 million

Regulus Therapeutics Inc.: Private sale, Jan 2009

Investors in this round

2 investors had bought by the notice of Nov 15, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Regulus Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garry Lynne Menzel · Executive Officer
  • Grantland Lynne Bryce · Executive Officer
  • Kleanthis Xanthopoulos · Executive Officer, Director
  • B. Lynne Parshall · Director
  • Barry E. Greene · Director
  • David Baltimore · Director
  • John E. Maraganore · Director
  • Stanley Crooke · Director
  • Stelios E. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the value of certain shares of the Issuer's Series A Preferred Stock issued in exchange for LLC membership interests in connection with the conversion of the Issuer from an LLC into a corporation under Delaware law.”
  • On a merger: “The reported transaction includes the exchange of LLC membership interests for shares of Series A Preferred Stock of the Issuer in connection with the conversion of the Issuer from an LLC into a corporation under Delaware law”

Signed by Grantland Bryce, Corp. Secretary. Source: SEC Form D, newest notice filed Nov 15, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Regulus Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2021).

    SEC Form D · Dec 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2021

That is all the official record says: Regulus Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Regulus Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Alnylam Pharmaceuticals, Inc.Companynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Isis Pharmaceuticals IncCompanynot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2012)SEC Form 3
Sarissa Capital Master Fund II LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Regulus Therapeutics Inc.
NameRoleNamed in
Christopher AkerExecutive officerDec 2021
Cris CalsadaExecutive officerDec 2021
Denis DryginExecutive officerDec 2021
Joseph HaganExecutive officerDec 2021
Christopher R. AkerExecutive officerMay 2019
Daniel R. ChevallardExecutive officerMay 2019
Joseph P. HaganExecutive officerMay 2019
Kleanthis XanthopoulosExecutive officerFeb 2014
Neil Lynne GibsonExecutive officerFeb 2014
Garry Lynne MenzelExecutive officerOct 2012
Grantland Lynne BryceExecutive officerNov 2010
Alice S. HuangDirectorDec 2021
David BaltimoreDirectorDec 2021
Hugh H. RosenDirectorDec 2021
Jake R. NunnDirectorDec 2021
Joseph HaganDirectorDec 2021
Kathryn J. CollierDirectorDec 2021
Pascale H. WitzDirectorDec 2021
Simos H. SimeonidisDirectorDec 2021
Stelios PapadopoulosDirectorDec 2021
William H. RastetterDirectorDec 2021
David R. BaltimoreDirectorMay 2019
Joseph P. HaganDirectorMay 2019
Kathryn L. CollierDirectorMay 2019
Stelios R. PapadopoulosDirectorMay 2019
B. Lynne ParshallDirectorFeb 2014
Bruce L.A. CarterDirectorFeb 2014
Douglas E. WilliamsDirectorFeb 2014
John H. MaraganoreDirectorFeb 2014
Kleanthis XanthopoulosDirectorFeb 2014
Mark G. FolettaDirectorFeb 2014
Stelios H. PapadopoulosDirectorFeb 2014
Barry E. GreeneDirectorOct 2012
John E. MaraganoreDirectorOct 2012
Stanley CrookeDirectorOct 2012
Stelios E. PapadopoulosDirectorOct 2012